(Z)-2-aminobutenoic acid : A 2,3-dehydroamino acid resulting from the formal elimination of water from the side-chain of threonine. [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 6449989 |
| SCHEMBL ID | 360722 |
| CHEBI ID | 18820 |
| CHEBI ID | 48305 |
| CHEBI ID | 48306 |
| MeSH ID | M0234671 |
| Synonym |
|---|
| 2-butenoic acid, 2-amino- |
| dhb amino acid |
| 20748-08-7 |
| dehydrobutyrine |
| anhydrothreonine |
| (z)-dehydrobutyrine |
| 2-ammoniobut-2-enoate |
| DB03720 |
| (z)2,3-didehydrobutyrine |
| (2z)-2-aminobut-2-enoic acid |
| alpha,beta-dehydroaminobutyric acid |
| (z)-2-aminobutenoic acid |
| 71018-10-5 |
| CHEBI:18820 |
| 2-aminobut-2-enoic acid |
| CHEBI:48305 |
| CHEBI:48306 |
| 2-aminobut-2-enoic acid zwitterion |
| 2-azaniumylbut-2-enoate |
| C17234 |
| (z)-2-aminobut-2-enoic acid |
| a,b-dhaba |
| 2-butenoic acid, 2-amino-, (z)- |
| 66ql1s96rm , |
| unii-66ql1s96rm |
| z-dehydrobutyrine |
| SCHEMBL360722 |
| cis-2-amino-2-butenoic acid |
| 2-butenoic acid, 2-amino-, (2z)- |
| (2z)-dehydrobutyrine |
| dehydrobutyrine, (2z)- |
| aminocrotonic acid |
| Q27094626 |
| Q27104608 |
| STARBLD0014382 |
| (2z)-2-amino-2-butenoic acid |
| DTXSID401309522 |
| Class | Description |
|---|---|
| threonine derivative | An amino acid derivative resulting from reaction of threonine at the amino group or the carboxy group, or from the replacement of any hydrogen of threonine by a heteroatom. The definition normally excludes peptides containing threonine residues. |
| 2,3-dehydroamino acid | A dehydroamino acid whose side-chain contains a double bond at the 2-3 position. |
| enamine | An amine RNR'R'' where R has a double bond adjacent to the amine nitrogen. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 24 (100.00%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacterial Disease | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Bacterial Infections | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Benign Neoplasms | 0 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cataract | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cataract, Membranous | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Dehydration | 0 | 2023 | 2023 | 1.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Neoplasms | 0 | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |